Environmental Toxicology · 2015 · 18 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOral OncologyCancer Cell SignalingOncology PharmacologyOral Anticancer AgentsOral CarcinogenesisSquamous Cell CarcinomaAnticancer ActivityCancer Cell Proliferation InhibitionCell Cycle Arrest SignalingEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase Signaling
Helioxanthin, an active compound from Taiwania cryptomerioides Hayata, has been shown to have various biological activities. However, their anticancer effect in oral squamous cell carcinoma has not been well established yet. Helioxanthin inhibited the proliferation of oral squamous cell carcinoma cells in a dose-dependent manner by inducing G2/M phase arrest. Similarly, helioxanthin inhibited cyclooxygenase-2, (COX-2), phosphorylated EGFR, and extracellular-signal-regulated kinases (ERK) protein level and further reduced the nuclear accumulation of phosphorylated epidermal growth factor receptor (pEGFR) and activator protein-1(AP-1) family protein, c-fos. Moreover, helioxanthin at the dose of 20 and 30 mg kg−1 for 15 days reduced the tumor growth in animal model. This study demonstrated that Helioxanthin exerts its anticancer activity against oral cancer cells by downregulating EGFR/ERK/c-fos signaling pathway to inhibit COX-2 level and by activating cyclin-dependent kinase inhibitor (p27) to further induce G2/M cell cycle arrest. This helioxanthin may serve as a novel candidate for oral cancer prevention. © 2015 Wiley Periodicals, Inc. Environ Toxicol 31: 2045–2056, 2016.
39
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Swati Kulkarni, Janet S. Rader, Fan Zhang et al. · PubMed · 2001 · 332 citations
Medicine, Cancer Biology, Oncology +14